Until lecanemab and donanemab are granted regular FDA approval it’s very unlikely there will be a change in CMS’s current severely restrictive coverage policy. Once approved CMS will be inclined to relax coverage limits. This said, upon approval unfettered access will not be a plausible scenario.
Donanemab’s Data Look Promising, But It Won’t Lead To An Imminent Change In Medicare’s Severe Restrictions On Coverage Of Alzheimer’s Disease Biologics
